Antagonism by bioactive polyphenols against inflammation: A systematic view

Inflammation and Allergy - Drug Targets

Volumn 13, Issue 1, 2014, Pages 34-64

  Chu, Arthur J ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

ACE; AMPK; Antioxidation; Cytokine; FOXO; HIF; Inflammation; JAK STAT; MTORC1; NF B; Phytochemical; PI3K AkT; Polyphenol; TNF

Indexed keywords

AMYLOID; ANTHOCYANIN; BLOOD CLOTTING FACTOR; C REACTIVE PROTEIN; CAPSAICIN; CATECHIN; CHEMOKINE; CURCUMIN; CYTOKINE; GALLIC ACID; GELATINASE A; GENISTEIN; GINGEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; PATTERN RECOGNITION RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; POLYPHENOL; PROTEIN KINASE B; QUERCETIN; RESVERATROL; SERINE PROTEINASE OMI; THROMBOCYTE ACTIVATING FACTOR; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; ACTIVATING TRANSCRIPTION FACTOR 6; ALPHA INTERFERON; CAFFEIC ACID DERIVATIVE; HYPOXIA INDUCIBLE FACTOR; I KAPPA B; IMMUNOGLOBULIN; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 8; JANUS KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYPHENOL DERIVATIVE; PROTEIN IRE1; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXO; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; AUTOPHAGY; BACILLUS ANTHRACIS; BACTERIAL INFECTION; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; COMPLEMENT ACTIVATION; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DISEASE COURSE; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; HEPATITIS B; HOMEOSTASIS; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INFLAMMATION; INFLUENZA; NEOPLASM; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PARASITOSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TISSUE INJURY; UPREGULATION; VIRUS INFECTION; ARTICLE; AUTOIMMUNITY; CELL DIFFERENTIATION; DOWN REGULATION; EXTRACELLULAR MATRIX; INSULIN RESISTANCE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION;

ANIMALS; ANTIOXIDANTS; HOMEOSTASIS; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; NF-KAPPA B; PHYTOTHERAPY; POLYPHENOLS; SIGNAL TRANSDUCTION;

EID: 84893486058     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871528112666131119211002     Document Type: Review

References (236)

1. Nathan, C.; Ding, A. Nonresolving inflammation. Cell, 2010, 140(6), 871-882.
2. Heymann M. C.; Rösen-Wolff A. Contribution of the inflammasomes to autoinflammatory diseases and recent mouse models as research tools. Clin. Immunol., 2013, 147(3), 175-184.
3. Hotamisligil G. S. Inflammation and metabolic disorders. Nature, 2006, 444, 860-867.
4. Wellen, K. E.; Hotamisligil G. S. Inflammation, stress, and diabetes. J. Clin. Invest., 2005, 115, 1111-1119.
5. Nathan, C. Epidemic inflammation: pondering obesity. Mol. Med., 2008, 14, 485-492.
6. Clària, J.; González-Périz, A.; López-Vicario, C.; Rius, B.; Titos, E. New insights into the role of macrophages in adipose tissue inflammation and fatty liver disease: modulation by endogenous omega-3 fatty acid-derived lipid mediators. Front. Immunol., 2011, 2, 49.
7. Ross, R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med., 1999, 340, 115-126.
8. Libby, P. Inflammation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2012, 32, 2045-2051.
9. Swirski, F. K.; Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science, 2013, 339, 161-166.
10. Tabas, I.; Glass, C. K. Anti-Inflammatory therapy in chronic disease: challenges and opportunities. Science, 2013, 339, 166-172.
11. Wilkinson-Berka, J. L.; Rana, I.; Armani, R.; Agrotis, A. Reactive oxygen species, Nox and angiotensin II in angiogenesis: implications for retinopathy. Clin. Sci. (Lond), 2013, 124, 597-615.
12. Marnett, L. J.; Riggins, J. N.; West, J. D. Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. J. Clin. Invest., 2003, 111, 583-593.
13. Prousek, J. Fenton chemistry in biology and medicine. Pure. Appl. Chem., 2007, 79, 2325-2338.
14. Hwang, A. B.; Jeong, D. E.; Lee, S. J. Mitochondria and organismal longevity. Curr. Genomics, 2012, 13, 519-532.
15. Nathan C.; Ding A. SnapShot: Reactive Oxygen Intermediates (ROI). Cell, 2010, 140, 951-952.
16. Dizdaroglu M. Oxidatively induced DNA damage: mechanisms, repair and disease. Cancer Lett., 2012, 327, 26-47.
17. Vurusaner, B, Poli, G, Basaga, H. Tumor suppressor genes and ROS: complex networks of interactions. Free Radic. Biol. Med., 2012, 52, 7-18.
18. Mantovani, A. Molecular pathways linking inflammation and cancer. Curr. Mol. Med., 2010, 10, 369-373.
19. Grivennikov, S. I.; Greten, F. R.; Karin, M. Immunity, inflammation, and cancer. Cell, 2010, 140, 883-899.
20. Coussens, L. M.; Zitvogel, L.; Palucka, A. K. Neutralizing tumorpromoting chronic inflammation: a magic bullet? Science, 2013, 339, 286-291.
21. Odegaard, J. I.; Chawla, A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science, 2013, 339, 172-177.
22. Wang, C.; Burkhardt, B. R.; Guan, Y.; Yang, J. Role of pancreaticderived factor in type 2 diabetes: evidence from pancreatic β cells and liver. Nutr. Rev., 2012, 70(2), 100-106.
23. Glass, C. K.; Saijo, K.; Winner, B.; Marchetto, M. C.; Gage F. H. Mechanisms underlying inflammation in neurodegeneration. Cell, 2010, 140, 918-934.
24. Liu, T. F.; Brown, C. M.; El Gazzar, M.; McPhail, L.; Millet, P.; Rao, A.; Vachharajani, V. T.; Yoza, B. K.; McCall, C. E. Fueling the flame: bioenergy couples metabolism and inflammation. J. Leukoc. Biol., 2012, 92(3), 499-507.
25. Shay, J. E.; Celeste Simon, M. Hypoxia-inducible factors: crosstalk between inflammation and metabolism. Semin. Cell Dev. Biol., 2012, 23(4), 389-394.
26. Biswas, S. K.; Chittezhath, M.; Shalova, I. N.; Lim, J. Y. Macrophage polarization and plasticity in health and disease. Immunol. Res., 2012, 53(1-3), 11-24.
27. Fullerton, J. N.; O'Brien, A. J.; Gilroy, D. W. Pathways mediating resolution of inflammation: when enough is too much. J. Pathol., 2013, 231(1), 8-20.
28. Ariel, A.; Serhan, C. N. New lives given by cell death: macrophage differentiation following their encounter with apoptotic leukocytes during the resolution of inflammation. Front. Immunol., 2012, 3, 4.
29. Korns D.; Frasch S. C.; Fernandez-Boyanapalli R.; Henson P. M.; Bratton D. L. Modulation of macrophage efferocytosis in inflammation. Front. Immunol., 2011, 2, 57.
30. Takeuchi, O.; Akira, S. Pattern recognition receptors and inflammation. Cell, 2010, 140(6), 805-820.
31. Tang, D.; Kang, R.; Coyne, C. B.; Zeh, H. J.; Lotze, M. T. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol. Rev., 2012, 249(1), 158-175.
32. Lisboa, R. A.; Andrade, M. V.; Cunha-Melo, J. R.; Toll-like receptor activation and mechanical force stimulation promote the secretion of matrix metalloproteinases 1, 3 and 10 of human periodontal fibroblasts via p38, JNK and NF-kB. Arch. Oral Biol., 2013, 58(6), 731-739.
33. Endale, M.; Park, S. C.; Kim, S.; Kim, S. H.; Yang, Y.; Cho, J. Y.; Rhee, M. H. Quercetin disrupts tyrosine-phosphorylated phosphatidylinositol 3-kinase and myeloid differentiation factor-88 association, and inhibits MAPK/AP-1 and IKK/NF-κB-induced inflammatory mediators production in RAW 264. 7 cells. Immunobiology, 2013, 218 (12), 1452-1467.
34. Bosisio, D.; Polentarutti, N.; Sironi, M.; Bernasconi, S.; Miyake, K.; Webb, G. R.; Martin, M. U.; Mantovani, A.; Muzio, M. Stimulation of toll-like receptor 4 expression in human mononuclear phagocytes by interferon-gamma: a molecular basis for priming and synergism with bacterial lipopolysaccharide. Blood, 2002, 99(9), 3427-3431.
35. Kaufmann, S. H.; Dorhoi A. Inflammation in tuberculosis: interactions, imbalances and interventions. Curr. Opin. Immunol., 2013, 25(4), 441-449.
36. Reinhard, K.; Huber, M.; Lohoff, M.; Visekruna, A. The role of NF-κB activation during protection against Leishmania infection. Int. J. Med. Microbiol., 2012, 302(4-5), 230-235.
37. D'Elia, R. V.; Harrison, K.; Oyston, P. C.; Lukaszewski, R. A.; Clark, G. C. Targeting the "cytokine storm" for therapeutic benefit. Clin. Vaccine Immunol., 2013, 20(3), 319-327.
38. Epperson, M. L.; Lee, C. A.; Fremont, D. H. Subversion of cytokine networks by virally encoded decoy receptors. Immunol. Rev., 2012, 250(1), 199-215.
39. Zeremski, M.; Petrovic, L. M.; Talal, A. H. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J. Viral Hepat., 2007, 14(10), 675-687.
40. Chisari, F. V.; Isogawa, M.; Wieland, S. F. Pathogenesis of hepatitis B virus infection. Pathol. Biol. (Paris), 2010, 58(4), 258-266.
41. Tasca, K. I.; Calvi, S. A.; Souza, Ldo, R. Immunovirological parameters and cytokines in HIV infection. Rev. Soc. Bras. Med. Trop., 2012, 45(6), 663-669.
42. Leemans, J. C.; Cassel, S. L.; Sutterwala, F. S. Sensing damage by the NLRP3 inflammasome. Immunol. Rev., 2011, 243(1), 152-162.
43. Yang, C. S.; Shin, D. M.; Jo, E. K. The Role of NLR-related Protein 3 Inflammasome in Host Defense and Inflammatory Diseases. Int. Neurourol. J., 2012, 16(1), 2-12.
44. Markiewski, M. M.; DeAngelis, R. A.; Lambris, J. D. Complexity of complement activation in sepsis. J. Cell Mol. Med., 2008, 12(6A), 2245-2254.
45. Laplante, M.; Sabatini, D. M. mTOR signaling in growth control and disease. Cell, 2012, 149, 274-293.
46. Guertin, D. A.; Sabatini, D. M. Defining the role of mTOR in cancer. Cancer Cell, 2007, 12, 9-22.
47. Karar, J.; Maity, A. PI3K/AKT/mTOR Pathway in angiogenesis. Front. Mol. Neurosci., 2010, 4, 51.
48. Hotamisligil, G. S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell, 2010, 140(6), 900-917.
49. Janko, C.; Franz, S.; Munoz, L. E.; Siebig, S.; Winkler, S.; Schett, G.; Lauber, K.; Sheriff, A.; van der Vlag, J.; Herrmann, M. CRP/anti-CRP antibodies assembly on the surfaces of cell remnants switches their phagocytic clearance toward inflammation. Front. Immunol., 2012, 2, 70.
50. Foley, J. F. Focus issue: understanding mechanisms of inflammation. Sci. Signal., 2013, 6(258), eg2.
51. Gilmore, T. Rel/NF-kB Transcription Factors. 2009, www. nfkb. org.
52. Tilstra, J. S.; Clauson, C. L.; Niedernhofer, L. J.; Robbins, P. D. NF-κB in Aging and Disease. Aging Dis., 2011, 2(6), 449-465.
53. Chu, W. M. Tumor necrosis factor. Cancer Lett., 2013, 328, 222-225.
54. Eltzschig, H. K.; Carmeliet P. Hypoxia and inflammation. N. Engl. J. Med., 2011, 364(7), 656-665.
55. Imtiyaz, H. Z.; Simon, M. C. Hypoxia-inducible factors as essential regulators of inflammation. Curr. Top. Microbiol. Immunol., 2010, 345, 105-120.
56. Scholz, C. C.; Taylor, C. T. Targeting the HIF pathway in inflammation and immunity. Curr. Opin. Pharmacol., 2013, 13(14), 646-653.
57. Jiang, S.; Wang, W.; Miner, J.; Fromm, M. Cross regulation of sirtuin 1, AMPK, and PPARγ in conjugated linoleic acid treated adipocytes. PLoS One, 2012, 7(11), e48874.
58. Laplante, M.; Sabatini, D. M. An emerging role of mTOR in lipid biosynthesis. Curr. Biol., 2009, 19, R1046-R1052.
59. Marone, R.; Cmiljanovic, V.; Giese, B.; Wymann, M. P. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim. Biophys. Acta, 2008, 1784(1), 159-185.
60. Reedquist, K. A.; Ludikhuize, J.; Tak, P. P. Phosphoinositide 3-kinase signalling and FoxO transcription factors in rheumatoid arthritis. Biochem. Soc. Trans., 2006, 34(Pt 5), 727-730.
61. Alcorn, M. J.; Booth, J. L.; Coggeshall, K. M.; Metcalf, J. P. Adenovirus type 7 induces interleukin-8 production via activation of extracellular regulated kinase 1/2. J. Virol., 2001, 75(14), 6450-6459.
62. O'Shea, J. J.; Plenge, R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity, 2012, 36(4), 542-550.
63. Egwuagu, C. E. STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. Cytokine, 2009, 47(3), 149-156.
64. Huang, L. Y.; Chen, P.; Xu, L. X.; Zhou, Y. F.; Zhang, Y. P.; Yuan, Y. Z. Fractalkine upregulates inflammation through CX3CR1 and the Jak-Stat pathway in severe acute pancreatitis rat model. Inflammation, 2012, 35(3), 1023-1030.
65. Paz-Filho, G.; Mastronardi, C.; Franco, C. B.; Wang, K. B.; Wong, M. L.; Licinio, J. Leptin: molecular mechanisms, systemic proinflammatory effects, and clinical implications. Arq. Bras. Endocrinol. Metabol., 2012, 56(9), 597-607.
66. Eltzschig, H. K.; Sitkovsky, M. V.; Robson, S. C. Purinergic signaling during inflammation. N. Engl. J. Med., 2012, 367(24), 2322-2333.
67. Chu, A. J. Blood coagulation as an intrinsic pathway for proinflammation: a mini review. Inflamm. Allergy Drug Targets, 2010, 9, 32-44.
68. Chu, A. J. Role of tissue factor in thrombosis: coagulationinflammation-thrombosis circuit. Front. Biosci., 2006, 11, 256-271.
69. Noda, M.; Sasaki, K.; Ifuku, M.; Wada, K. Multifunctional effects of bradykinin on glial cells in relation to potential antiinflammatory effects. Neurochem. Int., 2007, 51(2-4), 185-191.
70. Suzuki, Y.; Ruiz-Ortega, M.; Lorenzo, O.; Ruperez, M.; Esteban, V.; Egido, J. Inflammation and angiotensin II. Int. J. Biochem. Cell Biol., 2003, 35(6), 881-900.
71. Xie, J.; Méndez, J. D.; Méndez-Valenzuela, V.; Aguilar-Hernández, M. M. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal., 2013, 25(11), 2185-2197.
72. Thompson, D.; Pepys, M. B.; Wood, S. P. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure, 1999, 7 (2), 169-77.
73. Syrovets, T.; Lunov, O.; Simmet, T. Plasmin as a proinflammatory cell activator. J. Leukoc. Biol., 2012, 92(3), 509-519.
74. Li, X.; Syrovets, T.; Simmet, T. The serine protease plasmin triggers expression of the CC-chemokine ligand 20 in dendritic cells via Akt/NF-κB-dependent pathways. J. Biomed. Biotechnol., 2012, 2012, 186710.
75. Milner, C. M.; Higman, V. A.; Day, A. J. TSG-6: a pluripotent inflammatory mediator? Biochem. Soc. Trans., 2006, 34(Pt 3), 446-450.
76. Bryan, N.; Ahswin, H.; Smart, N.; Bayon, Y.; Wohlert, S.; Hunt, J. A. Reactive oxygen species (ROS)-a family of fate deciding molecules pivotal in constructive inflammation and wound healing. Eur. Cell Mater., 2012, 24, 249-261.
77. Naik, E.; Dixit, V. M. Mitochondrial reactive oxygen species drive proinflammatory cytokine production. J. Exp. Med., 2011, 208, 417-420.
78. Bonizzi, G.; Piette, J.; Schoonbroodt, S.; Greimers, R.; Havard, L.; Merville, M. P.; Bours, V. Reactive oxygen intermediate-dependent NF-kappaB activation by interleukin-1beta requires 5-lipoxygenase or NADPH oxidase activity. Mol. Cell Biol., 1999, 19, 1950-1960.
79. Clark, R. A.; Valente, A. J. Nuclear factor kappa B activation by NADPH oxidases. Mech. Ageing Dev., 2004, 125, 799-810.
80. Geiszt, M.; Leto, T. L. The Nox family of NAD(P)H oxidases: host defense and beyond. J. Biol. Chem., 2004, 279, 51715-51718.
81. Harrison, D.; Griendling, K. K.; Landmesser, U.; Hornig, B.; Drexler, H. Role of oxidative stress in atherosclerosis. Am. J. Cardiol., 2003, 91, 7A-11A.
82. 2 levels induce hepcidin via signal transducer and activator of transcription 3 (STAT3). J. Biol. Chem., 2012, 287, 37472-37482.
83. Nauseef, W. M. Biological Roles for the NOX Family NADPH Oxidases. J. Biol. Chem., 2008, 283, 16961-16965.
84. Harrison, R. Physiological roles of xanthine oxidoreductase. Drug Metab. Rev., 2004, 36, 363-375.
85. Lee, I. T.; Yang, C. M. Role of NADPH oxidase/ROS in proinflammatory mediators-induced airway and pulmonary diseases. Biochem. Pharmacol., 2012, 84(5), 581-590.
86. Schaecher, K.; Goust, J. M.; Banik, N. L. The effects of calpain inhibition on IkB alpha degradation after activation of PBMCs: identification of the calpain cleavage sites. Neurochem. Res., 2004, 29(7), 1443-1451.
87. Chatzigeorgiou, A.; Lyberi, M.; Chatzilymperis, G.; Nezos, A.; Kamper, E. CD40/CD40L signaling and its implication in health and disease. Biofactors, 2009, 35(6), 474-483.
88. Hassan, G. S.; Merhi, Y.; Mourad, W. CD40 ligand: a neoinflammatory molecule in vascular diseases. Immunobiology, 2012, 217(5), 521-532.
89. Rizvi, M.; Pathak, D.; Freedman, J. E.; Chakrabarti S. CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol. Med., 2008, 14(12), 530-538.
90. Amin, K. The role of mast cells in allergic inflammation. Respir. Med., 2012, 106(1), 9-14.
91. Nogueira-Machado, J. A.; de Oliveira Volpe, C. M. HMGB-1 as a target for inflammation controlling. Recent Pat. Endocr. Metab. Immune Drug Discov., 2012, 6(3), 201-209.
92. Bae, J. S. Role of high mobility group box 1 in inflammatory disease: focus on sepsis. Arch. Pharm. Res., 2012, 35(9), 1511-1523.
93. Salminen, A.; Hyttinen, J. M.; Kaarniranta, K. AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan. J. Mol. Med. (Berl), 2011, 89(7), 667-676.
94. Tzivion, G.; Hay, N. PI3K-AKT-FoxO axis in cancer and aging. Biochim. Biophys. Acta, 2011, 1813(11), 1925-1931.
95. Hwang, J. W.; Rajendrasozhan, S.; Yao, H.; Chung, S.; Sundar, I. K.; Huyck, H. L.; Pryhuber, G. S.; Kinnula, V. L; Rahman, I. FOXO3 deficiency leads to increased susceptibility to cigarette smoke-induced inflammation, airspace enlargement, and chronic obstructive pulmonary disease. J. Immunol., 2011, 187(2), 987-998.
96. Zhou, W.; Cao, Q.; Peng, Y.; Zhang, Q. J.; Castrillon, D. H.; DePinho, R. A.; Liu, Z. P. FoxO4 inhibits NF-kappaB and protects mice against colonic injury and inflammation. Gastroenterology, 2009, 137(4), 1403-1414.
97. Ouyang, W.; Beckett, O.; Ma, Q.; Paik, J. H.; DePinho, R. A.; Li, M. O. Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. Nat. Immunol., 2010, 11(7), 618-627.
98. Hedrick, S. M.; Hess Michelini, R.; Doedens, A. L.; Goldrath, A. W.; Stone, E. L. FOXO transcription factors throughout T cell biology. Nat. Rev. Immunol., 2012, 12(9), 649-661.
99. O'Neill, L. A.; Hardie, D. G. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature, 2013, 493, 346-355.
100. Liu, S.; Reilly, S. M.; Lee, C. H. Transcriptional repression of mitochondrial function in aging: a novel role for the silencing mediator of retinoid and thyroid hormone receptors co-repressor. Antioxid. Redox. Signal, 2013, 19(3), 299-309.
101. Johnson, S. C.; Rabinovitch, P. S.; Kaeberlein, M. mTOR is a key modulator of ageing and age-related disease. Nature, 2013, 493, 338-345.
102. Schenone, S.; Brullo, C.; Musumeci, F.; Radi, M.; Botta, M. ATPcompetitive inhibitors of mTOR: an update. Curr. Med. Chem., 2011, 18(20), 2995-3014.
103. Foster, J. G.; Blunt, M. D.; Carter, E.; Ward, S. G. Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies. Pharmacol. Rev., 2012, 64(4), 1027-1054.
104. Błajecka, K.; Borgström, A.; Arcaro A. Phosphatidylinositol 3-kinase isoforms as novel drug targets. Curr. Drug Targets, 2011, 12(7), 1056-1081.
105. Ghigo, A.; Damilano, F.; Braccini, L.; Hirsch, E. PI3K inhibition in inflammation: Toward tailored therapies for specific diseases. Bioessays, 2010, 32(3), 185-196.
106. Chen, H. W.; Lin, A. H.; Chu, H. C.; Li, C. C.; Tsai, C. W.; Chao, C. Y.; Wang, C. J.; Lii, C. K.; Liu, K. L. Inhibition of TNF-α-induced inflammation by andrographolide via down-regulation of the PI3K/Akt signaling pathway. J. Nat. Prod., 2011, 74(11), 2408-2413.
107. Guha, M.; Mackman, N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J. Biol. Chem., 2002, 277, 32124-32132.
108. Martin, M.; Rehani, K.; Jope, R. S.; Michalek, S. M. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol., 2005, 6, 777-784.
109. Takada, Y.; Fang, X.; Jamaluddin, M. S.; Boyd, D. D.; Aggarwal, B. B. Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J. Biol. Chem., 2004, 279, 39541-39554.
110. Wang, H.; Brown, J.; Martin, M. Glycogen synthase kinase 3: A point of convergence for the host inflammatory response. Cytokine, 2011, 53(2), 130-140.
111. O'Shea, J. J.; Holland, S. M.; Staudt, L. M. JAKs and STATs in immunity, immunodeficiency, and cancer. N. Engl. J. Med., 2013, 368(2), 161-170.
112. Tremblay, C.; Paradis, M.; Doré, M. Expression of E-and Pselectin in tumor necrosis factor-induced dermatitis in dogs. Vet. Pathol., 2001, 38, 261-8.
113. Ichiyasu, H.; Suga, M.; Matsukawa, A.; Iyonaga, K.; Mizobe, T.; Takahashi, T.; Ando, M. Functional roles of MCP-1 in Propionibacterium acnes-induced, T cell-mediated pulmonary granulomatosis in rabbits. J. Leukoc. Biol., 1999, 65, 482-491.
114. Ito, H. Anti-interleukin-6 therapy for Crohn's disease. Curr. Pharm. Des., 2003, 9, 295-305.
115. Verma, S.; Li, S. H.; Badiwala, M. V.; Weisel, R. D.; Fedak, P. W.; Li, R. K.; Dhillon, B. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation, 2002, 105, 1890-1896.
116. Fisher, C. J. Jr.; Dhainaut, J. F.; Opal, S. M.; Pribble, J. P.; Balk, R. A.; Slotman, G. J. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebocontrolled trial: Phase III rhIL-1ra Sepsis Syndrome Study Group. J. Am. Med. Assoc., 1994, 271, 1836-1843.
117. Remick, D.; Manohar, P.; Bolgos, G.; Rodriguez, J.; Moldower, L.; Wollenberg, G. Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock, 1995, 4, 89-95.
118. Marquez-Velasco, R.; Bojalil, R.; Buelna, A.; Flores-Guzman, F.; Estevez-Ramirez, J.; Laguna, J.; Hernandez, A. M. Anti-tumor necrosis factor F(ab)2 antibody fragments protect in murine polymicrobial sepsis: concentration and early intervention are fundamental to the outcome. Inflamm. Res., 2006, 55, 378-384.
119. Panacek, E. A.; Marshall, J.; Albertson, T. E.; Johnson, D. H.; Johnson, S.; MacArthur, R. D. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit. Care Med., 2004, 32, 21730-21782.
120. Abraham, E.; Anzueto, A.; Gutierrez, G.; Tessler, S.; San Pedro, G.; Wunderink, R. Double-blind randomized controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock: NORASEPT II Study Group. Lancet, 1998, 351, 929-933.
121. Abraham, E.; Laterre, P. F.; Garbino, J.; Pingleton, S.; Butler, T.; Dugernier, T. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1, 342 patients. Crit. Care Med., 2001, 29, 503-510.
122. He, M. M.; Smith, A. S.; Oslob, J. D.; Flanagan, W. M.; Braisted, A. C.; Whitty, A. Small-molecule inhibition of TNF-A. Science, 2005, 310, 1022-1025.
123. Krunkosky, T. M.; Fischer, B. M.; Martin, L. D.; Jones, N.; Akley, N. J.; Adler, K. B. Effects of TNF-alpha on expression of ICAM-1 in human airway epithelial cells in vitro. Signaling pathways controlling surface and gene expression. Am. J. Respir. Cell Mol. Biol., 2000, 22, 685-692.
124. Harada, K.; Ohira, S.; Isse, K.; Ozaki, S.; Zen, Y.; Sato, Y.; Nakanuma, Y. Lipopolysaccharide activates nuclear factor-kappaB through toll-like receptors and related molecules in cultured biliary epithelial cells. Lab. Invest., 2003, 83, 1657-1667.
125. Tamai, R.; Asai, Y.; Hashimoto, M.; Fukase, K.; Kusumoto, S.; Ishida, H. Cell activation by monosaccharide lipid A analogues utilizing Toll-like receptor 4. Immunology, 2003, 110, 66-72.
126. Meng, G.; Rutz, M.; Schiemann, M.; Metzger, J.; Grabiec, A.; Schwandner, R. Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J. Clin. Invest., 2004, 113, 1473-1481.
127. Bozinovski, S.; Jones, J.; Beavitt, S. J.; Cook, A. D.; Hamilton, J. A.; Anderson, G. P. Innate immune responses to LPS in mouse lung are suppressed and reversed by neutralization of GM-CSF via repression of TLR-4. Am. J. Physiol. Lung Cell Mol. Physio., 2004, 286, L877-885.
128. Verbon, A.; Meijers, J. C.; Spek, C. A.; Hack, C. E.; Pribble, J. P.; Turner, T. Effects of IC14, an anti-CD14 antibody, on coagulation and fibrinolysis during low-grade endotoxemia in humans. J. Infect Dis., 2003, 187, 55-61.
129. Yang, Z.; Carter, C. D.; Miller, M. S.; Bochsler, P. N. CD14 and tissue factor expression by bacterial lipopolysaccharide-stimulated bovine alveolar macrophages in vitro. Infect. Immunity, 1995, 63, 51-56.
130. Mollnes, T. E.; Brekke, O. L.; Fung, M.; Fure, H.; Christiansen, D.; Bergseth, G. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin based human whole blood model of inflammation. Blood, 2002, 100, 1869-1877.
131. Kondo, A.; Koshihara, Y.; Togari, A. Signal transduction system for interleukin-6 synthesis stimulated by lipopolysaccharide in human osteoblasts. J. Interferon Cytokine Res., 2001, 21, 943-950.
132. Furst-Ladani, S.; Redl, H.; Haslberger, A.; Lubitz, W.; Messner, P.; Sleytr, U. B. Bacterial cell envelopes (ghosts) but not S-layers activate human endothelial cells (HUVECs) through sCD14 and LBP mechanism. Vaccine, 1999, 18, 440-448.
133. Olszyna, D. P.; Verbon, A.; Pribble, J. P.; Turner, T.; Axtelle, T.; van Deventer, S. J. Effect of IC14, an anti-CD14 antibody, on plasma and cell-associated chemokines during human endotoxemia. Eur. Cytokine Netw., 2003, 14, 158-162.
134. Matsushita, K.; Motani, R.; Sakuta, T.; Nagaoka, S.; Matsuyama, T.; Abeyama, K. Lipopolysaccharide enhances the production of vascular endothelial growth factor by human pulp cells in culture. Infect Immun., 1999, 67, 1633-1639.
135. Hasturk, H.; Kantarci, A.; Van Dyke, T. E. Oral inflammatory diseases and systemic inflammation: role of the macrophage. Front. Immunol., 2012, 3, 118.
136. Levine, B.; Mizushima, N.; Virgin, H. W. Autophagy in immunity and inflammation. Nature, 2011, 469(7330), 323-335.
137. Serhan, C. N.; Chiang, N. Resolution phase lipid mediators of inflammation: agonists of resolution. Curr. Opin. Pharmacol., 2013, 13(4), 632-640.
138. Romano, M. Lipoxin and aspirin-triggered lipoxins. ScientificWorld J., 2010, 10, 1048-1064.
139. Bannenberg, G. L. Therapeutic applicability of anti-inflammatory and proresolving polyunsaturated fatty acid-derived lipid mediators. ScientificWorld J., 2010, 10, 676-712.
140. Morita, M.; Kuba, K.; Ichikawa, A.; Nakayama, M.; Katahira, J.; Iwamoto, R.; Watanebe, T.; Sakabe, S.; Daidoji, T.; Nakamura, S.; Kadowaki, A.; Ohto, T.; Nakanishi, H.; Taguchi, R.; Nakaya, T.; Murakami, M.; Yoneda, Y.; Arai, H.; Kawaoka, Y.; Penninger, J. M.; Arita, M.; Imai, Y. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell, 2013, 153(1), 112-125.
141. Trostchansky, A.; Bonilla, L.; González-Perilli, L.; Rubbo, H. Nitro-fatty acids: formation, redox signaling, and therapeutic potential. Antioxid. Redox. Signal., 2013, 19(11), 1257-1265.
142. Pavlov, V. A.; Tracey, K. J. The vagus nerve and the inflammatory reflex-linking immunity and metabolism. Nat. Rev. Endocrinol., 2012, 8(12), 743-754.
143. Singleton, K. D.; Beckey, V. E.; Wischmeyer, P. E. Glutamine prevents activation of NF-pB and stress kinase pathways, attenuates inflammatory cytokine release, and prevents acute respiratory distress syndrome (ARDS) following sepsis. Shock, 2005, 24, 583-589.
144. Spychalowicz, A.; Wilk, G.; Śliwa, T.; Ludew, D.; Guzik, T. J. Novel therapeutic approaches in limiting oxidative stress and inflammation. Curr. Pharm. Biotechnol., 2012, 13(13), 2456-2466.
145. Rhen, T.; Cidlowski, J. A. Anti-inflammatory action of glucocorticoids-new mechanisms for old drugs. N. Engl. J. Med., 2005, 353(16), 1711-1723.
146. Woodard, J.; Platanias, L. C. AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival. Biochem. Biophys. Res. Commun., 2010, 398(1), 135-139.
147. Bu, D. X.; Griffin, G.; Lichtman, A. H. Mechanisms for the antiinflammatory effects of statins. Curr. Opin. Lipidol., 2011, 22(3), 165-170.
148. Jougasaki, M.; Ichiki, T.; Takenoshita, Y.; Setoguchi, M. Statins suppress interleukin-6-induced monocyte chemoattractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. Br. J. Pharmacol., 2010, 159(6), 1294-1303.
149. Xing, X. Q.; Duan, S.; Wu, X. W.; Gan, Y.; Zhao, S. P.; Chen, P.; Wu, S. J. Atorvastatin reduces lipopolysaccharide-induced expression of C-reactive protein in human lung epithelial cells. Mol. Med. Rep., 2011, 4(4), 753-757.
150. Townsend, K. P.; Shytle, D. R.; Bai, Y.; San, N.; Zeng, J.; Freeman, M.; Mori, T.; Fernandez, F.; Morgan, D.; Sanberg, P.; Tan, J. Lovastatin modulation of microglial activation via suppression of functional CD40 expression. J. Neurosci. Res., 2004, 78(2), 167-176.
151. Meng, X.; Zhang, K.; Li, J.; Dong, M.; Yang, J.; An, G.; Qin, W.; Gao, F.; Zhang, C.; Zhang, Y. Statins induce the accumulation of regulatory T cells in atherosclerotic plaque. Mol. Med., 2012, 18, 598-605.
152. Ehrenstein, M. R.; Jury, E. C.; Mauri, C. Statins for atherosclerosis-as good as it gets? N. Engl. J. Med., 2005, 352(1), 73-75.
153. Nakao, T.; Shiota, M.; Tatemoto, Y.; Izumi, Y.; Iwao, H. Pravastatin induces rat aortic endothelial cell proliferation and migration via activation of PI3K/Akt/mTOR/p70 S6 kinase signaling. J. Pharmacol. Sci., 2007, 105(4), 334-341.
154. Yang, D.; Han, Y.; Zhang, J.; Chopp, M.; Seyfried, D. M. Statins enhance expression of growth factors and activate the PI3K/Aktmediated signaling pathway after experimental intracerebral hemorrhage. World J. Neurosci., 2012, 2(2), 74-80.
155. Li, W.; Liu, Y.; Mukhtar, M. M.; Gong, R.; Pan, Y.; Rasool, S. T.; Gao, Y.; Kang, L.; Hao, Q.; Peng, G.; Chen, Y.; Chen, X.; Wu, J.; Zhu, Y. Activation of interleukin-32 proinflammatory pathway in response to influenza A virus infection. PLoS One, 2008, 3(4), e1985.
156. Martínez-Ruiz, A.; Araújo, I. M.; Izquierdo-Álvarez, A.; Hernansanz-Agustín, P.; Lamas, S.; Serrador, J. M. Specificity in Snitrosylation: a short-range mechanism for NO signaling? Antioxid. Redox. Signal., 2013, 19(11), 1220-1235.
157. Anand, P.; Stamler, J. S. Enzymatic mechanisms regulating protein S-nitrosylation: implications in health and disease. J. Mol. Med. (Berl), 2013, 90(3), 233-244.
158. López-Sánchez, L. M.; López-Pedrera, C.; Rodríguez-Ariza, A. Proteomics insights into deregulated protein S-nitrosylation and disease. Expert Rev. Proteomics, 2010, 9(1), 59-69.
159. Curtale, G.; Mirolo, M.; Renzi, T. A.; Rossato, M.; Bazzoni, F.; Locati, M. Negative regulation of Toll-like receptor 4 signaling by IL-10-dependent microRNA-146b. Proc. Natl. Acad. Sci. U S A., 2013, 110(28), 11499-11504.
160. Ricklin, D.; Lambris, J. D. Complement-targeted therapeutics. Nat. Biotechnol., 2007, 25, 1265-1275.
161. Pritchard, K. Jr.; Ackerman, A. W.; Gross, E. R.; Stepp, D. W.; Shi, Y.; Fontana, J. T.; Baker, J. E.; Sessa, W. C. Heat shock protein 90 mediates the balance of nitric oxide and superoxide anion from endothelial nitric-oxide synthase. J. Biol. Chem., 2001, 276(21), 17621-17624.
162. Borges, T. J.; Wieten, L.; van Herwijnen, M. J.; Broere, F.; van der Zee, R.; Bonorino, C.; van Eden, W. The anti-inflammatory mechanisms of Hsp70. Front. Immunol., 2012, 3, 95.
163. Sato, S.; Fujita, N.; Tsuruo, T. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. USA, 2000, 97(20), 10832-10837.
164. Whitesell, L.; Bagatell, R.; Falsey, R. The stress response: implications for the clinical development of hsp90 inhibitors. Curr. Cancer Drug Targets, 2003, 3(5), 349-358.
165. Chu, A. J. Chapter II: Blood coagulation fuels inflammation implementing a blood coagulation-inflammation-thrombosis circuit. In: Handbook of Hematology Research. Tondre, R., Lebegue, C., Eds.; Nova Science Publishers, Inc.; 2010, pp. 33-86.
166. Kamio, N.; Hashizume, H.; Nakao, S.; Matsushima, K.; Sugiya, H. Plasmin is involved in inflammation via protease-activated receptor-1 activation in human dental pulp. Biochem. Pharmacol., 2008, 75, 1974-1980.
167. Arisato, T.; Sarker, K. P.; Kawahara, K.; Nakata, M.; Hashiguchi, T.; Osame, M.; Kitajima, I.; Maruyama, I. The agonist of the protease-activated receptor-1 (PAR) but not PAR3 mimics thrombin-induced vascular endothelial growth factor release in human smooth muscle cells. Cell Mol. Life Sci., 2003, 60, 1716-1724.
168. Asokananthan, N.; Graham, P. T.; Fink, J.; Knight, D. A.; Bakker, A. J.; McWilliam, A. S. Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. J. Immunol., 2002, 168, 3577-3585.
169. Khoufache, K.; Berri, F.; Nacken, W.; Vogel, A. B.; Delenne, M.; Camerer, E.; Coughlin, S. R.; Carmeliet, P.; Lina, B.; Rimmelzwaan, G. F.; Planz, O.; Ludwig, S.; Riteau, B. PAR1 contributes to influenza A virus pathogenicity in mice. J. Clin. Invest,. 2013, 123(1), 206-214.
170. Khoufache, K.; LeBouder, F.; Morello, E.; Laurent, F.; Riffault, S.; Andrade-Gordon, P.; Boullier, S.; Rousset, P.; Vergnolle, N.; Riteau, B. Protective role for protease-activated receptor-2 against influenza virus pathogenesis via an IFN-gamma-dependent pathway. J. Immunol., 2009, 182(12), 7795-7802.
171. Kida, Y.; Inoue, H.; Shimizu, T.; Kuwano, K. Serratia marcescens serralysin induces inflammatory responses through proteaseactivated receptor 2. Infect. Immun., 2007, 75, 164-174.
172. Temkin, V.; Kantor, B.; Weg, V.; Hartman, M. L.; Levi-Schaffer, F. Tryptase activates the mitogen-activated protein kinase/activator protein-1 pathway in human peripheral blood eosinophils, causing cytokine production and release. J. Immunol., 2002, 169, 2662-2669.
173. Kelso, E. B.; Lockhart, J. C.; Hembrough, T.; Dunning, L.; Plevin, R.; Hollenberg, M. D. Therapeutic promise of proteinase-activated receptor-2 antagonism in joint inflammation. J. Pharmacol. Exp. Ther., 2006, 316, 1017-1024.
174. Cenac, N.; Andrews, C. N.; Holzhausen, M.; Chapman, K.; Cottrell, G.; Andrade-Gordon, P.; Steinhoff, M.; Barbara, G.; Beck, P.; Bunnett, N. W.; Sharkey, K. A.; Ferraz, J. G.; Shaffer, E.; Vergnolle, N. Role for protease activity in visceral pain in irritable bowel syndrome. J. Clin. Invest., 2007, 117, 636-647.
175. Slofstra, S. H.; Bijlsma, M. F.; Groot, A. P.; Reitsma, P. H.; Lindhout, T.; ten Cate, H.; Spek, C. A. Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation. Blood, 2007, 110, 3176-3182.
176. Mandard, S.; Patsouris, D. Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptors. PPAR Res., 2013, 2013, 613864.
177. Mohar, D. S.; Malik, S. The Sirtuin system: The Holy Grail of Resveratrol? J. Clin. Exp. Cardiolog., 2012, 3(11), pii: 216.
178. Speciale, A.; Chirafisi, J.; Saija, A.; Cimino, F. Nutritional antioxidants and adaptive cell responses: an update. Curr. Mol. Med., 2011, 11, 770-789.
179. Biasutto, L.; Mattarei, A.; Zoratti, M. Resveratrol and health: the starting point. Chembiochem., 2012, 13, 1256-1259.
180. Kanwar, J.; Taskeen, M.; Mohammad, I.; Huo, C.; Chan, T. H.; Dou, Q. P. Recent advances on tea polyphenols. Front. Biosci. (Elite Ed.), 2012, 4, 111-131.
181. Whiting, S.; Derbyshire, E.; Tiwari, B. K. Capsaicinoids and capsinoids. A? A systematic review of the evidence. Appetite, 2012, 59, 341-348.
182. Leiherer, A.; Mündlein, A.; Drexel, H. Phytochemicals and their impact on adipose tissue inflammation and diabetes. Vascul. Pharmacol., 2013, 58, 3-20.
183. Siddiqui, A. M.; Cui, X.; Wu, R.; Dong W.; Zhou, M.; Hu, M.; Simms, H. H.; Wang, P. The anti-inflammatory effect of curcumin in an experimentalmodel of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-p. Crit. Care Med., 2006, 34, 1874-1882.
184. Marchiani, A.; Rozzo, C.; Fadda, A.; Delogu, G.; Ruzza, P. Curcumin and curcumin-like molecules: from spice to drugs. Curr. Med. Chem., 2013, 21(2), 204-222.
185. Noorafshan, A.; Ashkani-Esfahani, S. A review of therapeutic effects of curcumin. Curr. Pharm. Des., 2013, 19, 2032-2046.
186. Gupta, S. C.; Prasad, S.; Kim, J. H.; Patchva, S.; Webb, L. J.; Priyadarsini, I. K.; Aggarwal, B. B. Multitargeting by curcumin as revealed by molecular interaction studies. Nat. Prod. Rep., 2011, 28, 1937-1955.
187. Tsuda, S.; Egawa, T.; Ma, X.; Oshima, R.; Kurogi, E.; Hayashi, T. Coffee polyphenol caffeic acid but not chlorogenic acid increases 5'AMP-activated protein kinase and insulin-independent glucose transport in rat skeletal muscle. J. Nutr. Biochem., 2012, 23, 1403-1409.
188. Akyol, S.; Ozturk, G.; Ginis, Z.; Armutcu, F.; Yigitoglu, M. R.; Akyol, O. In vivo and In vitro anti{dotless}neoplastic actions of caffeic ccid phenethyl ester (CAPE): therapeutic perspectives. Nutr. Cancer, 2013, 65, 515-526.
189. Domitrovic, R. The molecular basis for the pharmacological activity of anthocyans. Curr. Med. Chem., 2011, 18, 4454-4469.
190. Landis-Piwowar, K.; Chen, D.; Foldes, R.; Chan, T. H.; Dou, Q. P. Novel epigallocatechin gallate analogs as potential anticancer agents: a patent review (2009-present). Expert. Opin. Ther. Pat., 2013, 23, 189-202.
191. Singh, B. N.; Shankar, S.; Srivastava, R. K. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem. Pharmacol., 2011, 82(12), 1807-1821.
192. Steinmann, J.; Buer, J.; Pietschmann, T.; Steinmann, E. Antiinfective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br. J. Pharmacol., 2013, 168, 1059-1073.
193. Deby-Dupont, G.; Mouithys-Mickalad, A.; Serteyn, D.; Lamy, M.; Deby, C. Resveratrol and curcumin reduce the respiratory burst of Chlamydia-primed THP-1 cells. Biochem. Biophys. Res. Commun., 2005, 333, 21-27.
194. Chow, S. E.; Hshu, Y. C.; Wang, J. S.; Chen, J. K. Resveratrol attenuates oxLDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages. J. Appl. Physiol., 2007, 102, 1520-1527.
195. Petrônio, M. S.; Zeraik, M. L.; Fonseca, L. M.; Ximenes, V. F. Apocynin: chemical and biophysical properties of a NADPH oxidase inhibitor. Molecules, 2013, 18, 2821-2839.
196. Huang, X. F.; Li, H. Q.; Shi, L.; Xue, J. Y.; Ruan, B. F.; Zhu, H. L. Synthesis of resveratrol analogues, and evaluation of their cytotoxic and xanthine oxidase inhibitory activities. Chem. Biodivers., 2008, 5, 636-642.
197. Shen, L.; Ji, H. F. Insights into the inhibition of xanthine oxidase by curcumin. Bioorg. Med. Chem. Lett., 2009, 19, 5990-5993.
198. Aucamp, J.; Gaspar, A.; Hara, Y.; Apostolides Z. Inhibition of xanthine oxidase by catechins from tea (Camellia sinensis). Anticancer Res., 1997, 17, 4381-4385.
199. Schmidt, A. P.; Böhmer, A. E.; Antunes, C.; Schallenberger, C.; Porciúncula, L. O.; Elisabetsky, E.; Lara, D. R.; Souza, D. O. Antinociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1 adenosine receptors. Br. J. Pharmacol., 2009, 156, 163-172.
200. Nguyen, M. T.; Nguyen, N. T. Xanthine oxidase inhibitors from Vietnamese Blumea balsamifera L. Phytother. Res., 2012, 26, 1178-1181.
201. Bräunlich, M.; Slimestad, R.; Wangensteen, H.; Brede, C.; Malterud, K. E.; Barsett, H. Extracts, anthocyanins and procyanidins from Aronia melanocarpa as radical scavengers and enzyme inhibitors. Nutrients, 2013, 5, 663-678.
202. Sporn, M. B.; Liby, K. T. NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer, 2012, 12, 564-571.
203. Chu, A. J. Phytochemicals in disease preventions and interventions: a current view. In: Introduction to Functional Food Science: Textbook. Martirosyan, D. M., Ed.; Food Science Publishers, Inc.; 2013, Chapter 11: Vol. 1, pp. 155-194.
204. Manganiello, V.; Chung, J. H.; Park, S. J.; Ahmad, F.; Philp, A.; Baar, K.; Williams, T.; Luo, H.; Ke, H.; Rehmann, H.; Taussig, R.; Brown, A. L.; Kim, M. K.; Beaven, M. A.; Burgin, A. B. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell, 2012, 148, 421-433.
205. Shehzad, A.; Lee, Y. S. Molecular mechanisms of curcumin action: signal transduction. Biofactors, 2013, 39, 27-36.
206. Zhou, H.; Luo, Y.; Huang, S. Updates of mTOR inhibitors. Anticancer Agents Med. Chem., 2010, 10(7), 571-581.
207. Liu, M.; Wilk, S. A.; Wang, A.; Zhou, L.; Wang, R. H.; Ogawa, W.; Deng, C.; Dong, L. Q.; Liu, F. Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. J. Biol. Chem., 2010, 285(47), 36387-36394.
208. Johnson, S. M.; Gulhati, P.; Arrieta, I.; Wang, X.; Uchida, T.; Gao, T.; Evers, B. M. Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. Anticancer Res., 2009, 29(8), 3185-3190.
209. Beevers, C. S.; Chen, L.; Liu, L.; Luo, Y.; Webster, N. J.; Huang, S. Curcumin disrupts the mammalian target of rapamycin-raptor complex. Cancer Res., 2009, 69(3), 1000-1008.
210. Madan, E.; Prasad, S.; Roy, P.; George, J.; Shukla, Y. Regulation of apoptosis by resveratrol through JAK/STAT and mitochondria mediated pathway in human epidermoid carcinoma A431 cells. Biochem. Biophys. Res. Commun., 2008, 377(4), 1232-1237.
211. Chung, E. Y.; Kim, B. H.; Hong, J. T.; Lee, C. K.; Ahn, B. Nam, S.; Han, S. B.; Kim, Y. Resveratrol down-regulates interferon-γ-inducible inflammatory genes in macrophages: molecular mechanism via decreased STAT-1 activation. J. Nutr. Biochem., 2011, 22(10), 902-909.
212. Noh, K. T.; Chae, S. H.; Chun, S. H.; Jung, I. D.; Kang, H. K.; Park, Y. M. Resveratrol suppresses tumor progression via the regulation of indoleamine 2, 3-dioxygenase. Biochem. Biophys. Res. Commun., 2013, 431(2), 348-353.
213. Actis-Goretta, L.; Ottaviani, J. I.; Fraga, C. G. Inhibition of angiotensin converting enzyme activity by flavanol-rich foods. J. Agric. Food Chem., 2006, 54, 229-234.
214. Roy, D.; Perreault, M.; Marette, A. Insulin stimulation of glucose uptake in skeletal muscles and adipose tissues in vivo is NO dependent. Am. J. Physiol., 1998, 274, E692-699.
215. Fryer, L. G. D.; Hajduch, E.; Rencurel, F.; Salt, I. P.; Hundal, H. S.; Hardie, G.; Carling, D. Activation of glucose transport by AMPactivated kinase via stimulation of nitric oxide synthesis. Diabetes, 2000, 49, 1978-1985.
216. Wallerath, T.; Deckert, G.; Ternes, T.; Anderson, H.; Li, H.; Witte, K.; Förstermann, U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation, 2002, 106, 1652-1658.
217. Shen, M.; Zhao, L.; Wu, R. X.; Yue, S. Q.; Pei, J. M. The vasorelaxing effect of resveratrol on abdominal aorta from rats and its underlying mechanisms. Vascul. Pharmacol., 2013, 58, 64-70.
218. Roberts, C. K.; Barnard, R. J.; Scheck, S. H.; Balon, T. W. Exercisestimulated glucose transport in skeletal muscle is nitric oxide dependent. Am. J. Physiol., 1997, 273, E220-225.
219. Kumar, S.; Narwal, S.; Kumar, V.; Prakash, O. α-glucosidase inhibitors from plants: A natural approach to treat diabetes. Pharmacogn. Rev., 2011, 5, 19-29.
220. Gomez-Pinilla, F.; Nguyen, T. T. Natural mood foods: the actions of polyphenols against psychiatric and cognitive disorders. Nutr. Neurosci., 2012, 15, 127-133.
221. Timmers, S.; Auwerx, J.; Schrauwen, P. The journey of resveratrol from yeast to human. Aging (Albany NY), 2012, 4, 146-158.
222. Bley, K.; Boorman, G.; Mohammad, B.; McKenzie, D.; Babbar, S. A comprehensive review of the carcinogenic and anticarcinogenic potential of capsaicin. Toxicol. Pathol., 2012, 40, 847-873.
223. Sung, B.; Prasad, S.; Yadav, V. R.; Aggarwal, B. B. Cancer cell signaling pathways targeted by spice-derived nutraceuticals. Nutr. Cancer, 2012, 64, 173-197.
224. Chen, M. J.; Shih, S. C.; Wang, H. Y.; Lin, C. C.; Liu, C. Y.; Wang, T. E.; Chu, C. H.; Chen, Y. J. Caffeic acid phenethyl ester inhibits epithelial-mesenchymal transition of human pancreatic cancer cells. Evid. Based Complement Alternat. Med., 2013, 2013, 270906.
225. Verma, S.; Singh, A.; Mishra, A. Gallic acid: molecular rival of cancer. Environ. Toxicol. Pharmacol., 2013, 35, 473-485.
226. Thomasset, S.; Teller, N.; Cai, H.; Marko, D.; Berry, D. P.; Steward, W. P.; Gescher, A. J. Do anthocyanins and anthocyanidins, cancer chemopreventive pigments in the diet, merit development as potential drugs? Cancer Chemother. Pharmacol., 2009, 64, 201-211.
227. Li, Y.; Kong, D.; Bao, B.; Ahmad, A.; Sarkar, F. H. Induction of cancer cell death by isoflavone: the role of multiple signaling pathways. Nutrients, 2011, 3, 877-896.
228. Meydani, M.; Hasan, S. T. Dietary polyphenols and obesity. Nutrients, 2011, 2, 737-751.
229. Saito, M.; Yoneshiro, T. Capsinoids and related food ingredients activating brown fat thermogenesis and reducing body fat in humans. Curr. Opin. Lipidol., 2013, 24, 71-77.
230. Higuchi, M.; Dusting, G. J.; Peshavariya, H.; Jiang, F.; Hsiao, S. T.; Chan, E. C.; Liu, G. S. Differentiation of human adipose-derived stem cells into fat involves reactive oxygen species and Forkhead box O1 mediated upregulation of antioxidant enzymes. Stem Cells Dev., 2013, 22, 878-888.
231. Ried, K.; Sullivan, T. R.; Fakler, P.; Frank, O. R.; Stocks, N. P. Effect of cocoa on blood pressure. Cochrane. Database Syst. Rev., 2012, 87(7), 484.
232. Aviram, M.; Fuhrman, B. Wine flavonoids protect against LDL oxidation and atherosclerosis. Ann. N. Y. Acad. Sci., 2002, 957, 146-161.
233. Smith, B. W.; Adams, L. A. Non-alcoholic fatty liver disease. Crit. Rev. Clin. Lab. Sci., 2011, 48(3), 97-113.
234. Kim, M. H.; Kang, K. S. Isoflavones as a smart curer for nonalcoholic fatty liver disease and pathological adiposity via ChREBP and Wnt signaling. Prev. Med., 2012, 54, S57-63.
235. Leng, S.; Zhang, W.; Zheng, Y.; Liberman, Z.; Rhodes, C. J.; Eldar-Finkelman, H.; Sun, X. J. Glycogen synthase kinase 3 beta mediates high glucose-induced ubiquitination and proteasome degradation of insulin receptor substrate 1. J. Endocrinol., 2010, 206(2), 171-181.
236. Dubreuil, J. D. Antibacterial and antidiarrheal activities of plant products against enterotoxinogenic Escherichia coli. Toxins, 2013, 5, 2009-2041.